食管癌：疗效评估与随访
Oesophageal cancer: assessment of response and follow up.
作者信息
Rankin S C
机构信息
Guy's & St. Thomas Foundation Trust, London, UK.
出版信息
Cancer Imaging. 2007 Oct 1;7 Spec No A(Special issue A):S67-9. doi: 10.1102/1470-7330.2007.9019.
Abstract
The prognosis for oesophageal cancer is poor with a median survival of 3-5 months and recurrences are frequent. The best chance of cure is successful surgery and pre-operative chemoradiotherapy is used to try and improve outcomes. However, patients may either not respond or may progress during therapy and it is important to differentiate the responders from non-responders. Clinical parameters such as weight gain and improvement in swallowing can be assessed but imaging is used in an attempt to improve outcomes.
摘要
食管癌的预后较差，中位生存期为3至5个月，且复发频繁。治愈的最佳机会是成功进行手术，术前放化疗用于尝试改善治疗效果。然而，患者可能对治疗无反应或在治疗期间病情进展，区分反应者和无反应者很重要。可以评估体重增加和吞咽改善等临床参数，但使用影像学检查以试图改善治疗效果。
相似文献
1
Oesophageal cancer: assessment of response and follow up.
Cancer Imaging. 2007 Oct 1;7 Spec No A(Special issue A):S67-9. doi: 10.1102/1470-7330.2007.9019.
2
CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study.
Chin Clin Oncol. 2016 Feb;5(1):13. doi: 10.3978/j.issn.2304-3865.2016.02.04.
3
Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: a Japanese multi-institutional study of 237 patients.
Radiat Oncol. 2017 Feb 20;12(1):38. doi: 10.1186/s13014-017-0780-5.
4
Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Ann Surg Oncol. 2013 Nov;20(12):4008-15. doi: 10.1245/s10434-013-3102-7. Epub 2013 Jul 10.
5
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1357-64. doi: 10.1245/s10434-015-4619-8. Epub 2015 May 27.
6
A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
Radiat Oncol. 2017 Mar 7;12(1):47. doi: 10.1186/s13014-017-0785-0.
7
Esophageal cancer.
J Natl Compr Canc Netw. 2008 Oct;6(9):818-49.
8
The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
J Surg Oncol. 2015 Nov;112(6):597-602. doi: 10.1002/jso.24050. Epub 2015 Sep 23.
9
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
Eur J Surg Oncol. 2019 Aug;45(8):1498-1504. doi: 10.1016/j.ejso.2019.03.020. Epub 2019 Mar 19.
10
Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma.
BMC Cancer. 2020 Feb 22;20(1):144. doi: 10.1186/s12885-020-6622-0.
引用本文的文献
1
Proposed follow up programme after curative resection for lower third oesophageal cancer.
World J Surg Oncol. 2010 Sep 4;8:75. doi: 10.1186/1477-7819-8-75.
本文引用的文献
1
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
J Clin Oncol. 2006 Oct 10;24(29):4692-8. doi: 10.1200/JCO.2006.06.7801. Epub 2006 Sep 11.
2
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer.
Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8. doi: 10.1007/s00259-005-0040-z. Epub 2006 Mar 21.
3
Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy.
Radiology. 2006 May;239(2):472-80. doi: 10.1148/radiol.2391050043. Epub 2006 Mar 16.
4
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60. doi: 10.1016/j.athoracsur.2004.04.046.
5
Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Br J Surg. 2004 Aug;91(8):1004-9. doi: 10.1002/bjs.4595.
6
Autopsy findings in patients after curative esophagectomy for esophageal carcinoma.
J Am Coll Surg. 2003 Jun;196(6):866-73. doi: 10.1016/s1072-7515(03)00116-9.
7
Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease.
Cancer. 2003 Apr 1;97(7):1616-23. doi: 10.1002/cncr.11228.
8
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
Ann Oncol. 2002 Mar;13(3):361-8. doi: 10.1093/annonc/mdf081.
9
Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma.
Gastrointest Endosc. 2002 May;55(6):655-61. doi: 10.1067/mge.2002.123273.
10
The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
J Thorac Cardiovasc Surg. 2000 Dec;120(6):1085-92. doi: 10.1067/mtc.2000.110464.
Zotero 插件